Peter Welford analyst JEFFERIES

Currently out of the existing stock ratings of Peter Welford, 25 are a BUY (53.19%), 16 are a HOLD (34.04%), 6 are a SELL (12.77%).

Peter Welford

Work Performance Price Targets & Ratings Chart

Analyst Peter Welford works at JEFFERIES with a stock forecast success ratio of 33.89% fulfilled within 353.78 days on average.

Peter Welford’s has documented 80 price targets and ratings displayed on 10 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on NVS, Novartis AG ADR at 16-Jan-2024.

Wall Street Analyst Peter Welford

Analyst best performing recommendations are on CGEN (COMPUGEN).
The best stock recommendation documented was for PLX (PROTALIX BIOTHERAPEUTICS) at 9/6/2016. The price target of $8 was fulfilled within 156 days with a profit of $1.8 (29.03%) receiving and performance score of 1.86.

Average potential price target upside

AZN AstraZeneca PLC ADR GSK GlaxoSmithKline PLC ADR PLX Protalix Biotherapeutics CGEN Compugen GLPG Galapagos NV ADR GMAB Genmab AS NVO Novo Nordisk A/S NVS Novartis AG ADR SNY Sanofi ADR RHHBY Roche Holding Ltd ADR

Analyst name

Rating

Current price target

Potential distance

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

80

$12.3 (18.17%)

83

2 months 9 days ago

0/3 (0%)

$19.52 (32.28%)

Buy

85

$17.3 (25.55%)

2 months 29 days ago

0/11 (0%)

$19.26 (29.30%)

Hold

70

$2.3 (3.40%)

3 months 18 days ago

4/5 (80%)

$2.71 (4.03%)

253

Buy

142.74

9 months 9 days ago

0/6 (0%)

$75.62 (112.66%)

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

Which stock is Peter Welford is most bullish on?

Potential upside of $19.37 has been obtained for NVS (NOVARTIS AG ADR)

Which stock is Peter Welford is most reserved on?

Potential downside of -$54.22 has been obtained for NVO (NOVO NORDISK A/S)

What Year was the first public recommendation made by Peter Welford?

On 2014

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?